Core Viewpoint - The company, Shuoshi Biological, has announced voluntary salary reductions for its top executives due to ongoing performance challenges, reflecting a commitment to address operational difficulties [1][2]. Group 1: Salary Reductions - Eight senior executives, including the chairman and general manager, have voluntarily reduced their salaries by 5% to 50%, effective from August 15 [1]. - The salary reductions are estimated to save the company approximately 3.5 million yuan annually, which is about 90% of the company's net profit for the first half of 2025 [1]. Group 2: Financial Performance - For the first half of 2025, the company reported revenue of 176 million yuan, a slight decrease of 1.05% year-on-year, while net profit dropped by 86.35% to 3.99 million yuan [1]. - The company's non-recurring net profit worsened from a loss of 2.12 million yuan in the previous year to a loss of 28.05 million yuan [1]. Group 3: Business Challenges - The company specializes in infectious disease testing and maternal and child health diagnostics, experiencing a significant revenue drop from 5.54 billion yuan in 2022 to 403 million yuan in 2023, resulting in a loss of 374 million yuan [2]. - The company plans to implement cost-cutting measures, optimize its supply chain, and expand into overseas markets to address cash flow issues and declining gross margins [2].